Hemophilia is a genetic bleeding disorder afflicting about 20,000 people in the US and over 400,000 people in the world. Severe hemophilia is characterized by frequent joint bleeding, resulting in debilitating arthropathy because of toxic iron depositions (e.g., hemosiderin) in synovium and cartilage. Development of a sensitive, non-invasive biomarker is of high importance to determine efficacy of costly treatment plans. In this study, we investigate the feasibility of ultrashort echo time-based QSM (UTE-QSM) to identify hemosiderin deposition and to provide a sensitive biomarker for joint disease in hemophilia.
This abstract and the presentation materials are available to members only; a login is required.